X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/08/2859133/37704/en/CytomX-Therapeutics-Announces-First-Patient-Dosed-with-CX-2051-a-Conditionally-Activated-EpCAM-Directed-ADC-in-a-Phase-1-Study-in-Patients-with-Advanced-Solid-Tumors.html
https://www.contractpharma.com/contents/view_breaking-news/2024-04-03/cytomx-achieves-5m-astellas-milestone/
https://www.globenewswire.com/news-release/2024/04/03/2856845/37704/en/CytomX-Therapeutics-Announces-Nomination-of-Second-Clinical-Candidate-in-Broad-PROBODY-T-Cell-Engaging-Bispecific-TCB-Collaboration-with-Astellas.html
https://www.globenewswire.com/news-release/2024/03/21/2850174/37704/en/CytomX-Therapeutics-Appoints-Dr-Zhen-Su-to-Board-of-Directors.html
https://www.globenewswire.com/news-release/2024/03/18/2847747/37704/en/CytomX-Therapeutics-Announces-Milestone-Achievement-in-PROBODY-T-Cell-Engaging-Bispecific-TCB-Collaboration-with-Astellas.html
https://www.fiercebiotech.com/biotech/bms-checks-out-next-gen-yervoy-pact-cytomx-taking-300m-biobucks-it
https://www.globenewswire.com//news-release/2024/03/11/2844158/37704/en/CytomX-Therapeutics-Reports-2023-Financial-Results-and-Provides-Business-Update.html
https://www.globenewswire.com//news-release/2024/03/04/2839546/37704/en/CytomX-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-March-11-2024.html
https://www.globenewswire.com//news-release/2024/02/27/2835950/37704/en/CytomX-Therapeutics-to-Present-at-Upcoming-March-Investor-Conferences.html
https://www.globenewswire.com//news-release/2024/01/24/2815209/37704/en/CytomX-Therapeutics-Announces-FDA-Clearance-of-IND-Applications-for-CX-2051-a-Probody-Antibody-Drug-Conjugate-ADC-Targeting-EpCAM-and-CX-801-a-Conditionally-Activated-Interferon-Al.html
Market Place
Share 
